Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Chronic Lymphocytic Leukemia

Loss of p53 and altered miR15-a/16-1→MCL-1 pathway in CLL: insights from TCL1-Tg:p53−/− mouse model and primary human leukemia cells

Leukemia volume 28, pages 118–128 (2014)Cite this article

Subjects

Abstract

Chronic lymphocytic leukemia (CLL) patients with deletion of chromosome 17p, where the p53 gene is located, often develop more aggressive disease with poor clinical outcomes. To investigate the underlying mechanisms for the highly malignant phenotype of 17p- CLL and to facilitate in vivo evaluation of potential drugs against CLL with p53 deletion, we have generated a mouse model with TCL1-Tg:p53−/− genotype. These mice develop B-cell leukemia at an early age with an early appearance of CD5+/IgM+ B cells in the peritoneal cavity and spleen, and exhibit an aggressive path of disease development and drug resistance phenotype similar to human CLL with 17p deletion. The TCL1-Tg:p53−/− leukemia cells exhibit higher survival capacity and are more drug resistant than the leukemia cells from TCL1-Tg:p53wt mice. Analysis of microRNA expression reveals that p53 deletion resulted in a decrease of miR-15a and miR-16-1, leading to an elevated expression of Mcl-1. Primary leukemia cells from CLL patients with 17p deletion also show a decrease in miR-15a/miR-16-1 and an increase in Mcl-1. Our study suggests that the p53/miR15a/16-1/Mcl-1 axis may be an important pathway that regulates Mcl-1 expression and contributes to drug resistance and aggressive phenotype in CLL cells with loss of p53.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  1. Caligaris-Cappio F, Gobbi M, Bofill M, Janossy G . Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia. J Exp Med 1982; 155: 623–628.

    Article  CAS  Google Scholar 

  2. Landis SH, Murray T, Bolden S, Wingo PA . Cancer statistics, 1998. CA Cancer J Clin 1998; 48: 6–29.

    Article  CAS  Google Scholar 

  3. Zenz T, Mertens D, Dohner H, Stilgenbauer S . Importance of genetics in chronic lymphocytic leukemia. Blood Rev 2011; 25: 131–137.

    Article  CAS  Google Scholar 

  4. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916.

    Article  CAS  Google Scholar 

  5. Leonard CJ, Canman CE, Kastan MB . The role of p53 in cell-cycle control and apoptosis: implications for cancer. Important Adv Oncol 1995;, 33–42.

  6. Zenz T, Krober A, Scherer K, Habe S, Buhler A, Benner A et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008; 112: 3322–3329.

    Article  CAS  Google Scholar 

  7. Zenz T, Frohling S, Mertens D, Dohner H, Stilgenbauer S . Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol 2010; 23: 71–84.

    Article  Google Scholar 

  8. Gonzalez D, Martinez P, Wade R, Hockley S, Oscier D, Matutes E et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol 2011; 29: 2223–2229.

    Article  Google Scholar 

  9. de Viron E, Michaux L, Put N, Bontemps F, van den Neste E . Present status and perspectives in functional analysis of p53 in chronic lymphocytic leukemia. Leuk Lymphoma 2012; 53: 1445–1451.

    Article  CAS  Google Scholar 

  10. Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 2002; 99: 6955–6960.

    Article  CAS  Google Scholar 

  11. Planelles L, Carvalho-Pinto CE, Hardenberg G, Smaniotto S, Savino W, Gomez-Caro R et al. APRIL promotes B-1 cell-associated neoplasm. Cancer Cell 2004; 6: 399–408.

    Article  CAS  Google Scholar 

  12. Zapata JM, Krajewska M, Morse HC 3rd, Choi Y, Reed JC . TNF receptor-associated factor (TRAF) domain and Bcl-2 cooperate to induce small B cell lymphoma/chronic lymphocytic leukemia in transgenic mice. Proc Natl Acad Sci USA 2004; 101: 16600–16605.

    Article  CAS  Google Scholar 

  13. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA 2006; 103: 7024–7029.

    Article  CAS  Google Scholar 

  14. Raveche ES, Salerno E, Scaglione BJ, Manohar V, Abbasi F, Lin YC et al. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood 2007; 109: 5079–5086.

    Article  CAS  Google Scholar 

  15. Santanam U, Zanesi N, Efanov A, Costinean S, Palamarchuk A, Hagan JP et al. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci USA 2010; 107: 12210–12215.

    Article  CAS  Google Scholar 

  16. Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ . Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 1996; 10: 456–459.

    CAS  PubMed  Google Scholar 

  17. Pepper C, Lin TT, Pratt G, Hewamana S, Brennan P, Hiller L et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 2008; 112: 3807–3817.

    Article  CAS  Google Scholar 

  18. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19: 1294–1305.

    Article  CAS  Google Scholar 

  19. Zenz T, Mohr J, Edelmann J, Sarno A, Hoth P, Heuberger M et al. Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway. Leuk Lymphoma 2009; 50: 510–513.

    Article  CAS  Google Scholar 

  20. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215–221.

    Article  CAS  Google Scholar 

  21. Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol 1988; 29: 152–163.

    Article  CAS  Google Scholar 

  22. Trachootham D, Zhang H, Zhang W, Feng L, Du M, Zhou Y et al. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood 2008; 112: 1912–1922.

    Article  CAS  Google Scholar 

  23. Pelicano H, Feng L, Zhou Y, Carew JS, Hileman EO, Plunkett W et al. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem 2003; 278: 37832–37839.

    Article  CAS  Google Scholar 

  24. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580–1589.

    CAS  PubMed  Google Scholar 

  25. Enzler T, Kater AP, Zhang W, Widhopf GF 2nd, Chuang HY, Lee J et al. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. Blood 2009; 114: 4469–4476.

    Article  CAS  Google Scholar 

  26. Huang P, Sandoval A, Van Den Neste E, Keating MJ, Plunkett W . Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia 2000; 14: 1405–1413.

    Article  CAS  Google Scholar 

  27. Aqeilan RI, Calin GA, Croce CM . miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 2010; 17: 215–220.

    Article  CAS  Google Scholar 

  28. Wang LL . Biology of osteogenic sarcoma. Cancer J 2005; 11: 294–305.

    Article  CAS  Google Scholar 

  29. Hollstein M, Sidransky D, Vogelstein B, Harris CC . p53 mutations in human cancers. Science 1991; 253: 49–53.

    Article  CAS  Google Scholar 

  30. Bennett WP, Hollstein MC, Hsu IC, Sidransky D, Lane DP, Vogelstein B et al. Mutational spectra and immunohistochemical analyses of p53 in human cancers. Chest 1992; 101 (3 Suppl): 19S–20S.

    Article  CAS  Google Scholar 

  31. Levine AJ, Momand J, Finlay CA . The p53 tumour suppressor gene. Nature 1991; 351: 453–456.

    Article  CAS  Google Scholar 

  32. Cordone I, Masi S, Mauro FR, Soddu S, Morsilli O, Valentini T et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood 1998; 91: 4342–4349.

    CAS  PubMed  Google Scholar 

  33. Levine AJ, Oren M . The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009; 9: 749–758.

    Article  CAS  Google Scholar 

  34. Chipuk JE, Green DR . Dissecting p53-dependent apoptosis. Cell Death Differ 2006; 13: 994–1002.

    Article  CAS  Google Scholar 

  35. Vucic D, Dixit VM, Wertz IE . Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nat Rev Mol Cell Biol 2011; 12: 439–452.

    Article  CAS  Google Scholar 

  36. Ploner C, Kofler R, Villunger A . Noxa: at the tip of the balance between life and death. Oncogene 2008; 27 (Suppl 1): S84–S92.

    Article  CAS  Google Scholar 

  37. Pietrzak M, Puzianowska-Kuznicka M . p53-dependent repression of the human MCL-1 gene encoding an anti-apoptotic member of the BCL-2 family: the role of Sp1 and of basic transcription factor binding sites in the MCL-1 promoter. Biol Chem 2008; 389: 383–393.

    Article  CAS  Google Scholar 

  38. Sampath D, Liu C, Vasan K, Sulda M, Puduvalli VK, Wierda WG et al. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood 2012; 119: 1162–1172.

    Article  CAS  Google Scholar 

  39. Calin GA, Croce CM . Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. Blood 2009; 114: 4761–4770.

    Article  CAS  Google Scholar 

  40. Merkel O, Asslaber D, Pinon JD, Egle A, Greil R . Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia. Cell Cycle 2010; 9: 2764–2768.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank BA Hayes and R LaPushin for their assistance in handling CLL samples. This work was supported in part by grants CA085563, CA100428 and CA016672 from the National Institutes of Health, grant RP110322 from the Cancer Prevention and Research Institute of Texas (CPRIT), and a grant from the CLL Global Research Foundation.

Author Contributions

Contributions: JL designed and performed research, analyzed data and drafted the manuscript; GC, L F, HP, FW, WZ, MAO, WL performed research and analyzed data; HA performed histology/pathology analysis; CMC contributed TCL1 transgenic mice; MJK identified clinical specimens, designed research and interpreted data; PH directed the study design, data analysis/interpretation and drafted the manuscript.

Author information

Authors and Affiliations

  1. Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    J Liu, G Chen, L Feng, W Zhang, H Pelicano, F Wang, M A Ogasawara, W Lu & P Huang

  2. The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, USA

    J Liu, M A Ogasawara & P Huang

  3. The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China

    W Zhang

  4. State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, China

    F Wang & P Huang

  5. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    H M Amin

  6. Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University Medical Center, Columbus, OH, USA

    C M Croce

  7. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    M J Keating

Authors
  1. J Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Pelicano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M A Ogasawara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. W Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H M Amin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C M Croce
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M J Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. P Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P Huang.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, J., Chen, G., Feng, L. et al. Loss of p53 and altered miR15-a/16-1→MCL-1 pathway in CLL: insights from TCL1-Tg:p53−/− mouse model and primary human leukemia cells. Leukemia 28, 118–128 (2014). https://doi.org/10.1038/leu.2013.125

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2013.125

Keywords

This article is cited by

Search

Advanced search

Quick links